Sarepta Therapeutics Inc
SRPT
Market Cap$3.56B
Close$
$153.22
323.3% upside
Current Fair Value
323.3% upsideUndervalued by 323.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.56 Billion |
|---|---|
| Enterprise Value | $3.92 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $2.47 |
| Beta | 0.84 |
| Outstanding Shares | 96,283,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 14.85 |
|---|---|
| PEG | 5.98 |
| Price to Sales | 1.91 |
| Price to Book Ratio | 2.41 |
| Enterprise Value to Revenue | 2.06 |
| Enterprise Value to EBIT | 16.69 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.37 |
| Debt to Equity | 0.96 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...